HC Wainwright reiterated their buy rating on shares of Concert Pharmaceuticals (NASDAQ:CNCE) in a research report sent to investors on Friday morning, TipRanks reports. HC Wainwright currently has a $25.00 price target on the biotechnology company’s stock.

Several other research firms have also recently commented on CNCE. Janney Montgomery Scott reissued a buy rating and issued a $10.00 price target (down from $13.00) on shares of Concert Pharmaceuticals in a report on Monday, September 30th. BidaskClub cut Concert Pharmaceuticals from a hold rating to a sell rating in a report on Saturday, September 28th. ValuEngine raised Concert Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, December 3rd. JMP Securities reissued an outperform rating on shares of Concert Pharmaceuticals in a report on Wednesday, January 22nd. Finally, SunTrust Banks reissued a buy rating and issued a $30.00 price target (up from $25.00) on shares of Concert Pharmaceuticals in a report on Wednesday, January 22nd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $16.88.

Shares of CNCE stock opened at $9.92 on Friday. The business’s 50 day moving average is $9.56 and its two-hundred day moving average is $8.88. Concert Pharmaceuticals has a twelve month low of $5.36 and a twelve month high of $17.83. The company has a market capitalization of $236.50 million, a P/E ratio of -2.99 and a beta of 1.06. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.14.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.13. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.35 million. Concert Pharmaceuticals had a negative return on equity of 55.06% and a negative net margin of 7,291.37%. As a group, equities analysts predict that Concert Pharmaceuticals will post -3.21 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE raised its holdings in Concert Pharmaceuticals by 587.5% during the second quarter. Bank of America Corp DE now owns 762,606 shares of the biotechnology company’s stock worth $9,151,000 after purchasing an additional 651,684 shares during the last quarter. Nuveen Asset Management LLC acquired a new position in Concert Pharmaceuticals during the second quarter worth $5,523,000. Ingalls & Snyder LLC raised its holdings in Concert Pharmaceuticals by 12.7% during the third quarter. Ingalls & Snyder LLC now owns 1,531,862 shares of the biotechnology company’s stock worth $9,007,000 after purchasing an additional 172,487 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Concert Pharmaceuticals by 679.6% during the third quarter. Russell Investments Group Ltd. now owns 126,103 shares of the biotechnology company’s stock worth $742,000 after purchasing an additional 109,928 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Concert Pharmaceuticals in the second quarter worth $1,223,000. 65.69% of the stock is owned by institutional investors and hedge funds.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.

Featured Story: What does the Producer Price Index (PPI) tell investors?

Analyst Recommendations for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.